It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA-sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic osteosarcoma lesions, 11 major cell clusters are identified based on unbiased clustering of gene expression profiles and canonical markers. The transcriptomic properties, regulators and dynamics of osteosarcoma malignant cells together with their tumor microenvironment particularly stromal and immune cells are characterized. The transdifferentiation of malignant osteoblastic cells from malignant chondroblastic cells is revealed by analyses of inferred copy-number variation and trajectory. A proinflammatory FABP4+ macrophages infiltration is noticed in lung metastatic osteosarcoma lesions. Lower osteoclasts infiltration is observed in chondroblastic, recurrent and lung metastatic osteosarcoma lesions compared to primary osteoblastic osteosarcoma lesions. Importantly, TIGIT blockade enhances the cytotoxicity effects of the primary CD3+ T cells with high proportion of TIGIT+ cells against osteosarcoma. These results present a single-cell atlas, explore intratumor heterogeneity, and provide potential therapeutic targets for osteosarcoma.
Osteosarcomas are difficult to treat and have a limited response to immunotherapy. Here, the authors analyse osteosarcomas at the single-cell level, and identify both the transdifferentiation of malignant cells and an array of immune cells that could have implications for metastasis and immunotherapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Oncology Department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China (GRID:grid.412528.8) (ISNI:0000 0004 1798 5117)
2 Orthopaedic Department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China (GRID:grid.412528.8) (ISNI:0000 0004 1798 5117)
3 Central Laboratory of the First Hospital of Nanchang, Nanchang, China (GRID:grid.479689.d)
4 Pathology Department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China (GRID:grid.412528.8) (ISNI:0000 0004 1798 5117)
5 Changzheng Hospital of Naval Military Medical University, Department of Orthopedic Oncology, Shanghai, China (GRID:grid.413810.f)
6 Queen’s Medical Research Institute, MRC Centre for Reproductive Health & Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom (GRID:grid.511172.1) (ISNI:0000 0004 0613 128X)
7 Southern Medical University, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471); Guangdong Provincial Key Laboratory of Single Cell Technology and Application, Guangzhou, China (GRID:grid.484195.5)
8 Medical College of Jinan University, Department of Biochemistry and Molecular Biology, Guangzhou, China (GRID:grid.258164.c) (ISNI:0000 0004 1790 3548)
9 Shanghai Jiao Tong University School of Medicine, Clinical Research Center, Ruijin Hospital, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)